HYMPAVZI (marstacimab) - Haemophilia
Opinions on drugs -
Posted on
May 21 2025
Reason for request
Inclusion on list
Summary of opinion
Unfavourable opinion for reimbursement in the MA indication:
“HYMPAVZI is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with:
- severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or
- severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.”
Clinical Benefit
| Insufficient |
The clinical benefit of HYMPAVZI (marstacimab) is insufficient in the MA indication. |
Clinical Added Value
| Not applicable |
Documents
English version
Contact Us
Évaluation des médicaments
